News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA Mulls Killing GlaxoSmithKline’s Avandia Safety Study
April 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. regulators are considering ending a safety study on GlaxoSmithKline's (GSK.L) diabetes drug Avandia, the Wall Street Journal reported on Sunday, saying the move could also jeopardize the drug's presence in the U.S market.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
FDA
Approvals
GlaxoSmithKline
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Earnings
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation
February 13, 2026
·
5 min read
·
Annalee Armstrong
Vaccines
Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
Rare diseases
‘Highly Impressive’ Data Propels BridgeBio’s Achondroplasia Drug Forward
February 12, 2026
·
2 min read
·
Tristan Manalac
Insights
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
February 12, 2026
·
1 min read
·
Jennifer Smith-Parker
